When do the patents on METHYLIN ER expire, and when will generic METHYLIN ER be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Specgx Llc	METHYLIN ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	075629-001	May 9, 2000	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Specgx Llc	METHYLIN ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	075629-002	May 9, 2000	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 22, 2026

METHYLIN ER Investment Scenario and Fundamentals Analysis: Patent, FDA, Exclusivity, and Generic/Biosimilar Risk

METHYLIN ER is an extended-release formulation of methylphenidate (central nervous system stimulant for ADHD). The investable “fundamentals” hinge on (1) US FDA exclusivity and Orange Book patent estate strength around the ER product, (2) remaining patent life for formulations and use claims, and (3) the practical competitive threat from authorized generics and additional generic methylphenidate ER entrants. The dominant valuation lever is near-term volume durability versus erosion at the first regulatory/IP “open gate” (Paragraph IV or otherwise).

Bottom line: Without the drug’s Orange Book listing-level detail (listed patents, listed drug name variants, and expiration dates) and the FDA approval/regulatory history specific to METHYLIN ER, a complete, execution-grade investment thesis cannot be produced without risking inaccuracies.

What is METHYLIN ER and how does it perform as an ADHD revenue product?

METHYLIN ER is a branded, extended-release methylphenidate product positioned for ADHD. In stimulant franchises, demand durability is usually driven by:

patient continuity (titration stability and prescriber familiarity),
payer preference and step edits,
supply and bioequivalence perceptions for ER generics,
and clinical interchangeability within methylphenidate ER classes.

Key fundamentals investors underwrite

Unit elasticity vs switching risk: ER methylphenidate generics can substitute if covered on formularies.
Coverage velocity: once a competitor is on formulary, switching can compress share.
Channel and inventory dynamics: stimulant product cycles often reflect pharmacy stocking patterns and DEA-controlled substance scheduling effects.

What patents protect METHYLIN ER in the US and when do they expire?

Featured-snippet answer: US patent protection for METHYLIN ER is determined by Orange Book “listed patents” tied to the specific FDA approved “active ingredient + dosage form” labeling for the ER product. Patent expiration depends on whether protection is from:

formulation/composition of matter,
method of manufacture,
dosing regimens or method-of-use,
and any pediatric exclusivity extensions.

Critical estate components investors model

Core composition/formulation patents (typically broader, longer tail).
Method-of-use patents (often narrower, sometimes easier to design around).
Manufacturing/process patents (relevance depends on generic process design).
Terminal disclaimers and patent term adjustments (shrink or extend effective exclusivity).

When does METHYLIN ER lose exclusivity in the US?

Exclusivity for an ER methylphenidate brand is not one date; it is the combination of:

patent expiration for the relevant Orange Book patents,
non-patent exclusivity (if any) tied to the NDA approval history,
and any exclusivity extensions (e.g., pediatric).

Investment relevance

The earliest “generic entry window” is the first moment a fully compliant abbreviated pathway can be triggered without infringing a still-live listed patent.
If multiple patents remain live, the “real” launch trigger shifts to later dates or settlement-driven design-arounds.

What is the Orange Book status of METHYLIN ER?

Orange Book status is the authoritative map of:

the listed drug identity (brand name as listed),
the active ingredient,
dosage form and strength,
and every listed patent (with expiration and submission type).

Modeling impact

A high count of expirations clustered late increases “effective exclusivity” and slows generic entry.
Sparse, early-expiring listings increase the likelihood of near-term Paragraph IV and faster erosion.

How many patents cover METHYLIN ER and how strong is the patent estate?

A credible “strength” score requires:

number of Orange Book patents,
remaining weighted life (years-to-expiration),
family breadth (continuations and continuation-in-part),
and whether claims are composition vs method vs process.

Investment framing

Generic challengers target the easiest path: expired patents, non-infringement, or invalidity hooks on the most attackable independent claims.
Brands with late-expiring formulation patents generally force longer design-around timelines.

What generic entry risks exist for METHYLIN ER (Paragraph IV ANDA)?

For small-molecule CNS brands, generic risk comes from:

ANDA filers seeking Section viii (carve-out) or full bioequivalence strategies,
Paragraph IV challenges to at least one listed patent,
and launch timing controlled by litigation and settlement.

Risk variables investors model

the presence of a single “blocking” patent versus a set of independently blocking patents,
likely litigation outcomes based on claim types (composition/formulation often more litigated),
and probability of a settlement that delays launch to a “safe harbor” date.

What patent litigation affects METHYLIN ER?

Patent litigation affects:

whether the challenger faces an injunction threat,
how quickly a court schedule moves,
and whether parties settle with a license and stipulated delay.

Investment underwrite points

cases with early Markman decisions can accelerate or reduce settlement value.
stipulations and consent judgments can convert an IP uncertainty into a fixed delay window.

Do authorized generics or retail pharmacy dynamics change METHYLIN ER’s downside?

In many branded stimulant franchises, downside is less about first generic entry and more about:

subsequent broader formulary adoption,
price compression from multiple strengths,
and pharmacy-level substitution at the point of dispensing.

What to model

share loss curve after first true generic competitor,
strength-by-strength competition (ER strengths can lag depending on ANDA approvals),
and the impact of contracted payer rebates.

How does METHYLIN ER compare with other methylphenidate ER products for IP and competition?

Competitive comparison typically clusters around:

other methylphenidate ER brands (different ER technologies),
and methylphenidate ER generics and AB-rated alternatives.

Investment lens

If competitors launch earlier due to cleaner patent positions, METHYLIN ER faces earlier revenue compression.
If competing ER products share similar process and formulation constraints, litigation can spill over to constrain the whole competitive set.

What formulation patents are typically asserted for ER methylphenidate products?

For ER methylphenidate franchises, the most litigated themes often include:

polymer matrices and release profiles,
coating or bead technologies affecting dissolution rate,
and manufacturing-related parameters affecting release kinetics.

Investment mapping

If METHYLIN ER’s estate is formulation-heavy, generic entrants often face longer development cycles and higher design-around cost.
If the estate is method-of-use heavy, risk can shift to labeling carve-outs, with regulatory and commercial negotiation implications.

What manufacturing/IP barriers exist for generic ER methylphenidate?

Manufacturing barriers arise from:

consistent ER release kinetics across scale,
control of dissolution specifications,
and establishing bioequivalence under FDA guidance for ER products.

Where IP matters most

process patents can constrain “how” a generic makes the product.
formulation patents constrain “what” the generic can use to replicate release.

What is the FDA regulatory pathway for METHYLIN ER, and what does it imply for generic timing?

Generic entry is usually via ANDA with bioequivalence; timing is driven by:

approval status and patent listing,
exclusivity/patent expiration windows,
and litigation outcomes or settlement.

Investment implication

Even if patents expire, launch often depends on FDA approval of the generic ANDA and manufacturing readiness.
For ER forms, regulatory review and stability/scale-up can delay initial shipments.

What dosing strengths and dosage forms exist for METHYLIN ER, and how does that affect market exposure?

Revenue exposure is typically strength-segmented:

each strength can have separate competitors and different time-to-market,
payer coverage and prior authorization can vary by strength.

Investment modeling

margin durability is often highest where fewer strengths have generic competition.

Commercial scenario analysis: Base, Downside, Upside

Because the requested drug-level patent and regulatory dataset is not provided here, only a framework can be stated without producing an execution-grade forecast.

Base case (moderate erosion)

Continued brand retention until the first meaningful patent or exclusivity hurdle is crossed.
Share loss begins at first generic entry; later erosion depends on formulary uptake and additional ANDA approvals.

Downside case (early entry and fast switching)

Multiple listed patents fall early via settlement or court outcomes.
Generic launches across several ER strengths within a short window.
Payer switching accelerates with aggressive rebate positioning.

Upside case (delayed generic entry)

Remaining estate includes late-expiring formulation/process patents.
Litigation leads to stipulated delay or stronger-than-expected claim resilience.
Additional competitors face slower ANDA approvals or development setbacks for ER kinetics.

Key due diligence checklist investors typically require before underwriting METHYLIN ER

Orange Book: all listed patents, listed drug codes, expiration dates, and patent types.
FDA: approval history for the exact ER product labeling and any exclusivity triggers.
Litigation: any ANDA Paragraph IV cases, counterclaims, Markman outcomes, and settlement terms.
Commercial: payer mix, rebate structure sensitivity, and channel inventory trends.
Competitive: mapping of other methylphenidate ER products and their entry timelines.

Key Takeaways

METHYLIN ER investment case is dominated by US patent/Orange Book timelines tied to the exact ER product listing and by the breadth and remaining life of formulation/process/use claims.
The practical downside risk is not only the first generic entry but the speed of formulary adoption across strengths.
The upside case usually requires late-expiring blocking patents and litigation outcomes that convert into stipulated launch delays.

FAQs

How do Orange Book listed patents determine when an ANDA for methylphenidate ER can launch?
What drives payer switching speed after the first generic methylphenidate ER approval?
Do method-of-use patents for ADHD stimulant products create design-around options for generics?
How do settlement agreements typically affect launch timing for Paragraph IV methylphenidate ER cases?
What manufacturing and dissolution controls most often determine ER bioequivalence for methylphenidate generics?

References

FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
Hatch-Waxman Amendments framework (Hatch-Waxman Act) and FDA ANDA regulations. U.S. Food and Drug Administration.
21 U.S.C. § 355(j) and related provisions governing ANDAs and Paragraph IV certifications.

METHYLIN ER Drug Patent Profile

When do Methylin Er patents expire, and when can generic versions of Methylin Er launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Methylin Er

AI Deep Research

Questions you can ask:

Summary for METHYLIN ER

US Patents and Regulatory Information for METHYLIN ER